Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Annals of Oncology

• Publication date

  2002-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/ANNONC/MDF155PMID 12123339
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody

  2001cited by this paper
• Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma.

  2000cited by this paper
• Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

  2000cited by this paper
• Response criteria for NHL: importance of 'normal' lymph node size and correlations with response rates.

  2000cited by this paper
• Practical Utility of the Revised European‐American Classification of Lymphoid Neoplasms for Japanese Non‐Hodgkin's Lymphomas

  2000cited by this paper
• European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.

  2000influential reference
• Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study.

  2000cited by this paper
• A UK multicentre phase II study of rituximab (chimaeric anti‐CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response

  2000influential reference
• IDEC‐C2B8 anti‐CD20 (Rituximab) immunotherapy in patients with low‐grade non‐Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients

  1999cited by this paper
• Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma.

  1999cited by this paper
• Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma.

  1999cited by this paper
• Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance.

  1999cited by this paper
• Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma.

  1998influential reference
• Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.

  1998cited by this paper
• Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group.

  1998influential reference
• Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies.

  1998cited by this paper
• B-cell lymphoma of 708 cases in Japan: incidence rates and clinical prognosis according to the REAL classification.

  1998cited by this paper
• Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

  1998influential reference
• Growth Inhibition of CD20‐positive B Lymphoma Cell Lines by IDEC‐C2B8 Anti‐CD20 Monoclonal Antibody

  1998cited by this paper
• Low-grade non-Hodgkin's lymphoma in northern Norway: treatment, outcome, and prognostic factors.

  1998cited by this paper
• Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone.

  1998cited by this paper
• IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.

  1997cited by this paper
• Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients.

  1997cited by this paper
• A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project

  1997cited by this paper
• Is the International Prognostic Index for aggressive lymphomas useful for low-grade lymphoma patients? Applicability to stage 111-IV patients

  1997cited by this paper
• Is the International Prognostic Index for aggressive lymphomas useful for low-grade lymphoma patients? Applicability to stage III-IV patients. The GOELAMS Group, France.

  1997cited by this paper
• High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma.

  1997cited by this paper
• A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project.

  1997cited by this paper
• Follicular large-cell lymphoma treated with intensive chemotherapy: an analysis of 89 cases included in the LNH87 trial and comparison with the outcome of diffuse large B-cell lymphoma. Groupe d'Etude des Lymphomes de l'Adulte.

  1997cited by this paper
• Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer.

  1997cited by this paper
• IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.

  1997influential reference
• Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.

  1996cited by this paper
• Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma.

  1996cited by this paper
• Prolonged survival in follicular non Hodgkins lymphoma is predicted by achievement of complete remission with initial treatment: results of a long-term study with multivariate analysis of prognostic factors.

  1996cited by this paper
• Mantle cell lymphoma-- an entity comes of age.

  1996cited by this paper
• Prognostic factors and a predictive model of follicular lymphoma: a 25-year study at a single institution in Japan.

  1996cited by this paper
• International Prognostic Index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades.

  1995cited by this paper
• A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study.

  1995cited by this paper
• Monoclonal Antibody against PRADl/Cyclin Dl Stains Nuclei of Tumor Cells with Translocation or Amplification at BCL‐1 Locus

  1994cited by this paper
• Immunohistochemical Analysis of Cyclin D1 Protein in Hematopoietic Neoplasms with Special Reference to Mantle Cell Lymphoma

  1994cited by this paper
• Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.

  1994cited by this paper
• Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma.

  1994cited by this paper
• A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.

  1994influential reference
• Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

  1994influential reference
• A Southwest Oncology Group study

  1993cited by this paper
• A predictive model for aggressive non-Hodgkin's lymphoma.

  1993cited by this paper
• Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy.

  1993cited by this paper
• Natural history of and therapy for the indolent non-Hodgkin's lymphomas.

  1993cited by this paper
• Toxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology Group.

  1993cited by this paper
• Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data.

  1992cited by this paper
• Mantle Cell Lymphoma A Proposal for Unification of Morphologic, Immunologic, and Molecular Data

  1992influential reference
• Low-grade follicular lymphomas: analysis of prognosis in a series of 281 patients.

  1991cited by this paper
• Follicular lymphomas: assessment of prognostic factors in 127 patients followed for 10 years.

  1991cited by this paper
• Phase I study of the combination of monthly carboplatin and weekly cisplatin.

  1991cited by this paper
• Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model.

  1991cited by this paper
• Antibody L26 recognizes an intracellular epitope on the B-cell-associated CD20 antigen.

  1990cited by this paper
• Malignant lymphoma in Hawaii‐Japanese: A retrospective morphologic survey

  1989influential reference
• Non-Hodgkin's lymphomas of follicular center cell type in Osaka, Japan.

  1989cited by this paper
• Follicular lymphoma: prognostic factors for response and survival.

  1986cited by this paper
• Lymphoproliferative diseases in Japan and Western countries: Proceedings of the United States--Japan Seminar, September 6 and 7, 1982, in Seattle, Washington.

  1983cited by this paper
• National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project.

  1982cited by this paper
• One-sample multiple testing procedure for phase II clinical trials.

  1982cited by this paper
• Toxicity and response criteria of the Eastern Cooperative Oncology Group

  1982cited by this paper
• Characterization of a human B lymphocyte-specific antigen.

  1980cited by this paper
• Evaluation of survival data and two new rank order statistics arising in its consideration.

  1966cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper
• National cancer institute sponsored study of classifications of non‐hodgkin's lymphomas. Summary and description of a working formulation for clinical usage

  year unknowncited by this paper
• Regression Models and Life-Tables

  year unknowncited by this paper

• Investigating rituximab-induced infusion-related reactions in patients with non-Hodgkin lymphoma, with a focus on follicular lymphoma: a retrospective observational study

  2026cites this paper
• Comparative inhibitory effects of bepotastine and diphenhydramine on rituximab-induced infusion reactions

  2025cites this paper
• Rituximab maintenance treatment outcomes in patients with relapsing neuromyelitis optica spectrum disorder: a monocentric retrospective analysis

  2024cites this paper
• Trends in non‐Hodgkin lymphoma mortality rate in Japan and the United States: A population‐based study

  2023cites this paper
• The Efficacy of Bepotastine Besilate Compared With Hydroxyzine Pamoate for Preventing Infusion Reactions to the First Dose of Rituximab in Patients With Non-Hodgkin Lymphoma: Protocol for a Phase II, Double-Blind, Multicenter Randomized Trial

  2023cites this paper
• Optimization of Rituximab Therapy in Adult Patients With PLA2R1-Associated Membranous Nephropathy With Artificial Intelligence

  2023cites this paper
• A Novel Class of On-Treatment Cancer Immunotherapy Biomarker: Trough Levels of Antibody Therapeutics in Peripheral Blood

  2022cites this paper
• [Rituximab immunomonitoring in autoimmune diseases: a support tool in clinical practice?]

  2021cites this paper
• A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial.

  2021cites this paper
• Epitope Mapping of an Anti-CD20 Monoclonal Antibody (C20Mab-60) Using Enzyme-Linked Immunosorbent Assay

  2021cites this paper
• RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL OF INTRAVENOUS BELIMUMAB IN PATIENTS

  2021cites this paper
• Cross-Validation of a Multiplex LC-MS/MS Method for Assaying mAbs Plasma Levels in Patients with Cancer: A GPCO-UNICANCER Study

  2021cites this paper
• Quantitative Clinical Pharmacology Supports the Bridging From i.v. Dosing and Approval of s.c. Rituximab in B‐Cell Hematological Malignancies

  2021cites this paper
• Relapses shortly after rituximab treatment in neuromyelitis optica spectrum disorder.

  2021cites this paper
• Prognosis of primary hepatic lymphoma: A US population-based analysis

  2020cites this paper
• Monoclonal Antibody Monitoring: Clinically Relevant Aspects, A Systematic Critical Review.

  2020cites this paper
• Cancer Chemotherapy: The Case for Therapeutic Drug Monitoring.

  2020cites this paper
• Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 1, monoclonal antibodies, antibody-drug conjugates and bispecific T-cell engagers.

  2020cites this paper
• Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group

  2020cites this paper
• Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial.

  2020cites this paper
• Towards rational cancer therapeutics: optimizing dosing, delivery, scheduling and combinations.

  2020cites this paper
• Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study

  2020cites this paper
• Seeking transpaRINcy for rituximab dosing in NMOSD - Authors' reply.

  2020cites this paper
• Anti-CD20 monoclonal antibodies in Systemic Lupus Erythematosus.

  2020cites this paper
• Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first‐line immunochemotherapy

  2019cites this paper
• Rituximab Serum Concentrations and Anti-Rituximab Antibodies During B-Cell Depletion Therapy for Myalgic Encephalopathy/Chronic Fatigue Syndrome.

  2019cites this paper
• Mechanisms of Resistance to Monoclonal Antibodies (mAbs) in Lymphoid Malignancies

  2019cites this paper
• Outcomes of combination therapy including rituximab for antibody-mediated rejection after lung transplantation

  2019cites this paper
• Rituximab dosing in hematological malignancies: an old question, revisited

  2019cites this paper
• Therapeutic drug monitoring of monoclonal antibodies: Applicability based on their pharmacokinetic properties.

  2019cites this paper
• Effects of Rituximab Including Long-term Maintenance Therapy in Children with Nephrotic Syndrome in a Single Center of Korea

  2018cites this paper
• Monoclonal Antibody Capture and Analysis Using Porous Membranes Containing Immobilized Peptide Mimotopes.

  2018cites this paper
• Phase II study of intensified rituximab induction and maintenance for low grade B cell lymphoma

  2017cites this paper
• Examens préthérapeutiques et surveillance des traitements par biomédicaments

  2017cites this paper
• Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group

  2017cites this paper
• Therapeutic monoclonal antibodies in clinical laboratory

  2017cites this paper
• Rituximab and Alemtuzumab for Chronic Lymphocytic Leukemia: Clinical Pharmacology and Therapeutic Results

  2017cites this paper
• Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report.

  2017cites this paper
• Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience

  2017cites this paper
• Optimizing drug development in oncology by clinical trial simulation: Why and how?

  2017cites this paper
• Theranostic of biopharmaceuticals

  2017cites this paper
• Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial.

  2016cites this paper
• Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients

  2016cites this paper
• Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: Translating TNF‐α experience to oncology

  2016cites this paper
• Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma

  2016cites this paper
• Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma

  2016influential citation
• The preclinical discovery of rituximab for the treatment of non-Hodgkin’s lymphoma

  2015cites this paper
• Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.

  2014cites this paper
• Development of antirituximab antibodies in children with nephrotic syndrome

  2014cites this paper
• A new frontier in haematology – combining pharmacokinetic with pharmacodynamic factors to improve choice and dose of drug

  2014cites this paper
• [Perioperative agranulocytosis induced by immunosuppressants in a renal graft recipient : a case report].

  2014cites this paper
• Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients

  2014cites this paper
• Variability in clinical and biological response to rituximab in autoimmune diseases: an opportunity for personalized therapy?

  2014cites this paper
• Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis.

  2013cites this paper
• Rituximab biosimilars

  2013cites this paper
• Cardiovascular Adverse Events Complicating the Administration of Rituximab: Report of Two Cases

  2013cites this paper
• Influence of FCGRT gene polymorphisms on pharmacokinetics of therapeutic antibodies

  2013cites this paper
• Rituximab therapy in nephrotic syndrome: implications for patients' management

  2013cites this paper
• Evidence for therapeutic drug monitoring of targeted anticancer therapies.

  2012cites this paper
• Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response

  2012cites this paper
• Population Pharmacokinetics of Rituximab in Patients With Chronic Lymphocytic Leukemia

  2012cites this paper
• Model-based design of rituximab dosage optimization in follicular non-Hodgkin's lymphoma.

  2012cites this paper
• Overview of Therapy for Glomerular Disease

  2011cites this paper
• Transition of thyroid autoantibodies by rituximab treatment for thyroid MALT lymphoma.

  2011cites this paper
• BM-ca is a newly defined type I/II anti-CD20 monoclonal antibody with unique biological properties.

  2011cites this paper
• Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma.

  2011cites this paper
• Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non‐Hodgkin lymphoma mostly pretreated with rituximab: A multicenter phase II study

  2011cites this paper
• Phase I study of LY2469298, an Fc‐engineered humanized anti‐CD20 antibody, in patients with relapsed or refractory follicular lymphoma

  2011cites this paper
• Model-based design of rituximab dosing optimization in follicular non-hodgkin lymphoma

  2011cites this paper
• Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1–2 study

  2010cites this paper
• UvA-DARE ( Digital Academic Repository ) B cells and B cell directed therapies in rheumatoid arthritis : towards personalized medicine

  2010cites this paper
• Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B‐cell non‐Hodgkin lymphoma: 7‐year follow‐up results

  2010cites this paper
• Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects

  2010cites this paper
• The Bone Marrow in Normal and Disease States

  2010cites this paper
• Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results.

  2009cites this paper
• Les Anticorps Monoclonaux, de la Production à l'utilisation en Oncologie

  2009cites this paper
• Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance.

  2009cites this paper
• Down-regulation of CD 20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies : its prevalence and clinical significance

  2009cites this paper
• [Molecular-targeted drugs. 1) Indications and the application of molecular-targeted drugs in hematological diseases].

  2009cites this paper
• [Pharmacokinetics (PK) of mAbs].

  2009cites this paper
• Analysis of reactivation of hepatitis B virus in the treatment of B cell non-Hodgkin’s lymphoma in Hokkaido

  2009cites this paper
• Prevention of hepatitis B virus reactivation under rituximab therapy.

  2009cites this paper
• Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20.

  2009cites this paper
• Évaluation et validation des tests diagnostiques dans le cadre du ciblage thérapeutique

  2009cites this paper
• Drug Safety Evaluation

  2009cites this paper
• 3．分子標的薬 1）血液疾患領域における分子標的薬の適応と使い方

  2009cites this paper
• Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma.

  2009cites this paper
• B cell targets in rheumatoid arthritis

  2009cites this paper
• Evaluation and validation of diagnostic tests for guiding therapeutic decisions.

  2009cites this paper
• Bioanalytical methods for the quantification of therapeutic monoclonal antibodies and their application in clinical pharmacokinetic studies

  2009cites this paper
• Pharmacocinétique des anticorps monoclonaux

  2009cites this paper
• Japanese phase II study of 90Y‐ibritumomab tiuxetan in patients with relapsed or refractory indolent B‐cell lymphoma

  2009cites this paper
• Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B‐cell non‐Hodgkin lymphoma

  2009cites this paper
• Rituximab in minimal change nephropathy and focal segmental glomerulosclerosis: report of four cases and review of the literature.

  2008cites this paper
• Treatment of follicular lymphoma: current status

  2008cites this paper
• Pharmacokinetic properties of rituximab.

  2008cites this paper
• Acute coronary syndromes complicating the first infusion of rituximab.

  2008cites this paper
• Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma.

  2008cites this paper
• A Case of Multiple Mucosa-associated Lymphoid Tissue Lymphoma of the Lung and Bronchus

  2007cites this paper
• Biotherapies: are they just like any other drugs?

  2007cites this paper